HighVista Strategies Boosts Stake in Agios Pharmaceuticals

Hedge fund increases ownership in biopharmaceutical company by 178.5%

Mar. 16, 2026 at 11:07am

Got story updates? Submit your updates here. ›

HighVista Strategies LLC, a hedge fund, has increased its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 178.5% in the third quarter, according to a recent 13F filing with the Securities and Exchange Commission (SEC). The fund now owns 195,298 shares of the biopharmaceutical company's stock, making it approximately 1.9% of HighVista's holdings.

Why it matters

Agios Pharmaceuticals is a prominent biopharmaceutical company focused on developing novel therapies for cancer and rare genetic diseases. The significant increase in HighVista's stake suggests the hedge fund sees strong potential in the company's pipeline and future prospects.

The details

According to the 13F filing, HighVista Strategies bought an additional 125,171 shares of Agios Pharmaceuticals during the third quarter, bringing its total ownership to 195,298 shares. This represents a 178.5% increase in the fund's position. Agios Pharmaceuticals now makes up approximately 1.9% of HighVista's overall portfolio.

  • HighVista Strategies increased its stake in Agios Pharmaceuticals during the third quarter of the year.

The players

HighVista Strategies LLC

A hedge fund that has increased its stake in Agios Pharmaceuticals by 178.5%, making the biopharmaceutical company one of its top 10 holdings.

Agios Pharmaceuticals, Inc.

A biopharmaceutical company focused on developing novel therapies for cancer and rare genetic diseases, whose stock is held by HighVista Strategies.

Got photos? Submit your photos here. ›

The takeaway

The significant increase in HighVista Strategies' stake in Agios Pharmaceuticals suggests the hedge fund sees strong potential in the biopharmaceutical company's future prospects and pipeline of novel therapies.